Anti-Rh(D) immunoglobulin belongs to the therapeutic class of immune globulins.

Anti-Rh(D) immunoglobulin primarily prevents Rh sensitization in Rh-negative individuals, particularly pregnant women. It is administered during pregnancy and after childbirth to neutralize any Rh-positive fetal blood cells that may have entered the maternal bloodstream. Additionally, RhIg is employed in situations like miscarriages, ectopic pregnancies, invasive prenatal procedures, and Rh-incompatible blood transfusions or organ transplants to prevent the development of Rh antibodies, safeguarding against the potential complications of Rh sensitization in subsequent pregnancies or medical scenarios.

Anti-Rh(D) immunoglobulin (RhIg) can be administered through two primary routes: intramuscular (IM) injection and intravenous (IV) injection. The doctor chooses the administration route based on the patient's needs and preferences.

Side effects of anti-Rh(D) immunoglobulin are generally rare but can include mild local reactions at the injection site, such as pain, redness, or swelling. Some individuals may experience a low-grade fever. Serious side effects, while extremely uncommon, may include severe allergic reactions (anaphylaxis), blood clots (thromboembolism), kidney issues, and the possibility of infection transmission, although this risk is minimal.

Anti-Rh(D) immunoglobulin can potentially trigger severe allergic reactions, including anaphylaxis, although such reactions are rare. Rare cases of blood clots (thromboembolism) have been reported with the use of this medication. There is still a very low risk of transmitting infectious agents through its use.

Healthcare providers should be prepared to manage allergic reactions and have appropriate emergency measures when administering Anti-Rh(D) immunoglobulin. Patients with a history of clotting disorders or conditions that increase the risk of clot formation need careful monitoring before taking this medication. Patients should be aware of the minimal risk of transmitting infectious agents through its use.

When using anti-Rh(D) immunoglobulin, healthcare providers should exercise precautions such as confirming the patient's Rh blood type, monitoring for allergic reactions (especially in those with known allergies), assessing clotting risk, closely observing patients with kidney issues, educating about infection transmission risks, considering vaccination timing, evaluating safety during pregnancy and breastfeeding, screening for hepatitis B, administering accurate dosages, being aware of potential drug interactions, ensuring proper storage, monitoring for Rh sensitization efficacy, adjusting dosages for pediatric and geriatric patients, and assessing patients with compromised immune systems or underlying conditions. These precautions help ensure the safe and effective use of this medication for each patient's specific clinical needs while minimizing potential risks.

1. Athina L. Yoham, Damian Casadesus, [Revised on 27th May 2021] [Accessed on 26 September 2023], https://www.ncbi.nlm.nih.gov/books/NBK557884/
2. CSL Behring GmbH, [Revised on Jun 2019] [Accessed on 26 September 2023], https://www.medicines.org.uk/emc/files/pil.6791.pdf
3. CSL Behring (NZ) Ltd, [Revised on Jun 2021] [Accessed on 26 September 2023], https://www.medsafe.govt.nz/profs/Datasheet/r/RhDimmunoglobulinVFinj.pdf 

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.